Mylan Inc. has sued the Food and Drug Administration to get generic versions of Pfizer Inc.’s Lipitor on the market in late June and block India’s Ranbaxy from receiving 180 days of marketing exclusivity for its version of the medicine.

Ranbaxy is expected to launch its generic Lipitor Nov. 30 under a settlement with Pfizer and remain free of multiple competitors for 180 days, as the first company to apply to sell a cheaper version of the world’s best selling prescription medicine. Get the full story »